What's Happening?
KalVista Pharmaceuticals, Inc. has announced its participation in the 25th Annual Needham Virtual Healthcare Conference, scheduled for April 15, 2026. The company will engage in a fireside chat, which will be accessible via a live audio webcast on their
website. KalVista is known for developing EKTERLY®, the first oral on-demand treatment for hereditary angioedema (HAE). The company continues to focus on delivering oral therapies for rare diseases with significant unmet needs, working closely with the global HAE community to enhance treatment and care.
Why It's Important?
KalVista's participation in the conference highlights its ongoing commitment to addressing rare diseases, an area with substantial unmet medical needs. The company's focus on hereditary angioedema and its innovative oral treatment options could significantly impact patient care and treatment accessibility. This event provides an opportunity for KalVista to showcase its advancements and engage with investors and stakeholders, potentially influencing future collaborations and investments in the rare disease sector.
